Uterine cancer Radiotherapy

Radiotherapy is a cancer treatment in which, depending on the technique, different types of radiation are used to kill cancer cells. After radiotherapy, the patient does not emit any radioactivity and can return to her normal private life.

The first treatment for uterine cancer is usually surgery. After surgical removal of the uterus, the end of the vagina is sutured together to form a vaginal stump. No additional treatment is required for low-risk tumors. However, sometimes the tumor characteristics require postoperative radiotherapy to reduce the likelihood of tumor recurrence. Radiotherapy can kill cancer cells that may still be present in the vaginal stump or in the pelvic lymph nodes. If post-operative radiotherapy is required, the patient is first given enough time to recover after the operation, usually between four to six weeks. This is followed by radiotherapy, which in selected cases is combined with chemotherapy to improve its effectiveness.

So-called definitive radiotherapy is used to cure uterine cancer, either alone or in combination with drug therapy. This occurs very rarely, for example in cases where surgery is not possible due to secondary diseases.

If the uterine cancer has already spread, so-called palliative radiotherapy can prevent or alleviate the symptoms caused by metastases, e.g. in the lungs or bones.

Each patient is discussed in detail by a panel of experts from all relevant specialist areas. After this discussion, the patient is presented with the optimal choice of treatment and her wishes and opinions are taken into account. Personal support is a matter of course for us.

Types of radiotherapy for uterine cancer

Two types of radiotherapy can be used for uterine cancer: external and internal.

In external radiation therapy, a linear accelerator is used to send high-energy X-rays to the tumor or remaining tumor cells in order to kill them in a targeted manner. External radiation therapy is carried out as an outpatient treatment, does not require anesthesia and can be easily integrated into everyday private and professional life. The treatments are not painful and each session only takes a few minutes. As a rule, it is carried out once a day for five weeks. The treatment only takes place on weekdays, therefore five times a week. At the USZ, we use only the latest technology to achieve a personalized and precise dose distribution in the tissue.

In postoperative internal radiation therapy, known as brachytherapy, a cylinder is inserted into the vagina up to the vaginal stump in order to destroy the tumor cells at close range. The radiation source is then placed directly into the cylinder and any remaining tumor cells are irradiated from a short distance. Brachytherapy with a vaginal cylinder is painless, does not require anesthesia and is performed as an outpatient treatment. If surgery was not possible and definitive radiotherapy is required, brachytherapy sources are inserted into the uterus under anesthesia or sedation to destroy the tumor. In brachytherapy, the beams only travel a short distance so that healthy tissue in the vicinity is optimally protected. After the treatment, the source is removed from the body and the patient can leave the hospital.

Brachytherapy is a clinical and scientific focus of Prof. Primoz Petric, an internationally recognized expert in this field, who passes on his knowledge at international congresses, courses and through publications. The USZ uses the latest technology of magnetic resonance or computer tomography-guided brachytherapy. This technique enables highly precise and personalized delivery of the radiation dose to the tumor or remaining tumor cells and minimizes the irradiation of normal tissue.

You will be looked after by internationally recognized experts in the research and treatment of gynaecological cancer. The irradiation of gynecological tumors with a modern magnetic resonance or CT-guided technique is a clinical and scientific focus of Prof. P. Petric. He passes on his knowledge in a large number of international courses and congresses and is active as an international expert in guideline commissions. He is involved in research and development activities that have an impact on the global field of cervical cancer radiotherapy.

The Department of Radiation Oncology at the USZ uses only the most modern techniques for precise and low side-effect radiation treatment of uterine cancer. State-of-the-art equipment and experienced medical staff contribute to treatment of optimum quality and safety.

Our team works closely with our colleagues in gynecology and medical oncology in order to guarantee “one-stop” treatment.

In clinical trials, we are continuously working on improving the treatment of uterine cancer to make it even more effective and tolerable. To the overview of currently open studies.

In the following, we will describe radiotherapy for the different types and stages of uterine cancer.

Uterine cancer with medium risk after surgery

If the tumor is classified as medium risk, additional radiotherapy is sometimes required to improve the treatment outcome and increase the chances of recovery. Depending on the clinical details, we can recommend either several applications of vaginal cylinder brachytherapy or a combination of external radiation with two applications of brachytherapy.

Uterine cancer with high risk after surgery

External radiation therapy with chemotherapy is recommended for tumors with a high risk profile in the removed tissue. In selected cases, two applications of brachytherapy can be added to improve the results.

Inoperable uterine cancer

In rare cases where surgery is not possible, good results can be achieved with radiotherapy alone. In such situations, five weeks of external radiation therapy are usually combined with four applications of brachytherapy, in which radioactive sources are introduced into the uterus to destroy the tumor. This treatment can also be combined with chemotherapy in selected cases.

Metastases of uterine cancer, e.g. in the brain or bones

Uterine cancer is an aggressive type of cancer that often forms metastases during the course of the disease: this is called metastasis. Common sites of metastasis are the lung, adrenal gland, bones, liver or brain. Radiotherapy is a highly effective method with few side effects to prevent or treat symptoms caused by metastases. This is usually done in combination with chemotherapy, immunotherapy or other targeted therapy. The smaller the metastases are and the earlier they are irradiated, the better the results. Today, metastases in the body can be treated in a focused manner in just a few effective radiation sessions.

For tumor foci in the abdominal area, e.g. liver or upper abdomen, we carry out body stereotactic radiotherapy (SBRT) on our MRI hybrid accelerator. State-of-the-art radiation technology is combined with MRI images. The radiation is thus carried out under MRI monitoring of the tumor, so that the highest precision is combined with the best imaging. Our clinic was the first in Switzerland to introduce this technology back in 2019. We are still the only clinic in German-speaking Switzerland to offer the highest level of expertise in this field.

Today, brain metastases are treated at our center in most patients by means of a single high-dose radiation treatment: this is called radiosurgery.

Metastases at other locations in the body can now also be treated in a focused manner in just a few effective radiation sessions. Metastatic uterine cancer is a clinical and scientific focus of our clinic. We pass on our knowledge in a large number of international courses and congresses. We are active as international experts in guideline commissions.

State-of-the-art equipment and experienced medical physicists and MTRAs contribute to treatment of optimum quality and safety. At the same time, we work closely with our colleagues in medical oncology to guarantee “one-stop” treatment. We also consult with our colleagues in palliative medicine at an early stage.

In clinical trials, we are continuously trying to improve the treatment of uterine cancer in order to make it even more effective and tolerable. To the overview of currently open studies.

  • ESMO-ESGO-ESTROConsensusConference onEndometrial Cancer: diagnosis, treatment andfollow-up. Colombo N, et al. Annals of Oncology 2016;27:16-41.
  • Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomized phase 3 trial. De Boer SM, et al. Lancet Oncol 2019;20:1273-85.
  • Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomized trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Creutzberg CL, et al. Lancet 2000;355:1404-11.
  • Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomized trial. Nout R, et al. Lancet 2010:375:816-823.
  • Characterization and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Guckenberger M, Lancet Oncol. 2020(1):e18-e28.

Responsible professionals

Claudia Linsenmeier, Dr. med.

Senior Attending Physician, Department of Radiation Oncology

Tel. +41 44 255 26 73
Specialties: Focus on breast/gynecology, Gastro-Intestinal Radio-Oncology, Pediatric radio-oncology

For patients

As a patient, you cannot register directly for a consultation. Please get a referral from your primary care physician, specialist.

Contact form

For referrering physicians

Simply assign your patient online or by email.

Tel. +41 44 255 35 66
Patient registration form

Responsible Department

Related diseases